Sequential chemoimmunotherapy with cisplatin, interferon-β and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice

Melanoma Research

Volumn 10, Issue 3, 2000, Pages 223-229

  Kubo, H ^a   Matsumoto, K ^a   Funahashi, M ^a   Takagi, H ^a   Kitajima, Y ^a   Taniguchi, S ^a   Saida, T ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin; Interferon ; Interleukin 2; Mouse melanoma; Sequential chemoimmunotherapy

Indexed keywords

BETA INTERFERON; CISPLATIN; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN G; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENCY; FEMALE; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENTIAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0033769737     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200010030-00003     Document Type: Article

References (25)

1. Effect of cisplatin upon expression of in vivo immune tumor resistance
2. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma
3. Chemoimmunotherapy of metastatic malignant melanoma. The Salpetriere hospital (SOMPS) experience
4. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy
5. Clinical study of DAV+IFN-β therapy (combination adjuvant therapy with intravenous DTIC, ACNU and VCR, and local injection of IFN-β) for malignant melanoma
6. Effect of natural interferon-β on the growth of melanoma cell lines
7. Monoclonal antibody to murine gamma interferon inhibits lymphokine-induced antiviral and macrophage tumoricidal activities
8. Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: Comparison with other methods of purification
9. Selection of successive tumour lines for metastasis
10. Simultaneous detection of TdT-mediated dUTP-biotin nick end-labeling (TUNEL)-positive cells and multiple immunohistochemical markers in single tissue sections
11. A new method to detect apoptosis in paraffin section in situ endlabeling of fragmented DNA
12. Sequential chemoimmunotherapy for metastatic melanoma
13. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
14. Improved results with the addition of interferon alfa-2a to dacarbazine in the treatment of patients with metastatic malignant melanoma
15. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: A pilot study
16. A phase II study of dacarbazine and cisplatin in combination with outpatient administered IL-2 in metastatic melanoma
17. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma
18. Final results of a prospective multicentric study on 91 metastatic malignant melanoma patients treated by chemoimmunotherapy with cisplatin, IL-2, and interferon-alfa
19. Enhanced induction of lymphokine-activated killer activity following a single dose of cisplatin in cancer patients
20. Antigen-specific activation of effector macrophages by IFN-γ-producing (Th1) T cell clones. Failure of IL-4-producing (Th2) T cell clones to activate effector function in macrophage
21. Interferon: A cytotoxic T-lymphocyte differentiation signal
22. IL-2 and IFN-γ are two necessary lymphokines in the development of cytolytic T-cells
23. Preferential effect of interferon-γ on the synthesis of HLA antigens and their mRNAs in human cells
24. Differences in expression of a variant actin between low and high metastatic B16 melanoma
25. Differential cell- and immunobiological properties of routine B16-F1 and F10 melanomas: Oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides